-
The 'ordinary' Arnie? Glen Powell reboots 'The Running Man'
-
Typhoon exposes centuries-old shipwreck off Vietnam port
-
French court to decide if ex-president Sarkozy can leave jail
-
China lifts sanctions on US units of South Korea ship giant Hanwha
-
Japan death row inmate's sister still fighting, even after release
-
Taylor sparks Colts to Berlin win as Pats streak hits seven
-
Dreyer, Pellegrino lift San Diego to 4-0 MLS Cup playoff win over Portland
-
Indonesia names late dictator Suharto a national hero
-
Fourth New Zealand-West Indies T20 washed out
-
Tanzania Maasai fear VW 'greenwashing' carbon credit scheme
-
Chinese businesswoman faces jail after huge UK crypto seizure
-
Markets boosted by hopes for deal to end US shutdown
-
Amazon poised to host toughest climate talks in years
-
Ex-jihadist Syrian president due at White House for landmark talks
-
Saudi belly dancers break taboos behind closed doors
-
The AI revolution has a power problem
-
Big lips and botox: In Trump's world, fashion and makeup get political
-
NBA champion Thunder rally to down Grizzlies
-
US senators reach deal that could end record shutdown
-
Weakening Typhoon Fung-wong exits Philippines after displacing 1.4 million
-
Lenny Wilkens, Basketball Hall of Famer as player and coach, dies
-
Sir Dave Lewis Appointed Diageo plc CEO
-
Griffin wins PGA Mexico title for third victory of the year
-
NFL makes successful return to Berlin, 35 years on
-
Lewandowski hat-trick helps Barca punish Real Madrid slip
-
George warns England against being overawed by the All Blacks
-
Lewandowski treble helps Barca beat Celta, cut gap on Real Madrid
-
Neves late show sends PSG top of Ligue 1, Strasbourg down Lille
-
Inter go top of Serie A after Napoli slip-up
-
Bezos's Blue Origin postpones rocket launch over weather
-
Hamilton upbeat despite 'nightmare' at Ferrari
-
Taylor sparks Colts to Berlin win, Pats win streak hits seven
-
Alcaraz and Zverev make winning starts at ATP Finals
-
Protests suspend opening of Nigeria heritage museum
-
Undav brace sends Stuttgart fourth, Frankfurt win late in Bundesliga
-
Roma capitalise on Napoli slip-up to claim Serie A lead
-
Liverpool up for the fight despite Man City masterclass, says Van Dijk
-
Two MLB pitchers indicted on manipulating bets on pitches
-
Wales rugby captain Morgan set to be sidelined by shoulder injury
-
After storming Sao Paulo podium, 'proud' Verstappen aims to keep fighting
-
US flights could 'slow to a trickle' as shutdown bites: transport secretary
-
Celtic close on stumbling Scottish leaders Hearts
-
BBC chief resigns after row over Trump documentary
-
Norris extends title lead in Sao Paulo, Verstappen third from pit-lane
-
Norris wins in Sao Paulo to extend title lead over Piastri
-
Man City rout Liverpool to mark Guardiola milestone, Forest boost survival bid
-
Man City crush Liverpool to mark Guardiola's 1,000 match
-
Emegha fires Strasbourg past Lille in Ligue 1
-
Howe takes blame for Newcastle's travel sickness
-
Pumas maul Wales as Tandy's first game in charge ends in defeat
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
A.Malone--AMWN